| Host |
Rabbit |
| Klon |
EP121 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Some prostate or breast cancers |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in N-terminus of human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Biocare Medical |
EP121 |
6 ml |
Ready-to-use |
CE/IVD |
PME415AA |
-
|
| Host |
Mouse |
| Klon |
NFI/20 |
| Format |
Lyophilised |
| Methode |
F, EL, WB |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human collagen type I |
Collagen I
|
Zytomed Systems GmbH |
NFI/20 |
100 µg |
Lyophilised |
RUO |
603-1954 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised (for 0.5 ml) |
| Methode |
F, P, EL |
| Vorbehandlung |
Pepsin |
| Verdünnung |
1:10 - 1:50 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Collagen type I from human placenta |
Collagen I
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Lyophilised (for 0.5 ml) |
RUO |
603-1955 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
F, P, IF, EL, WB |
| Verdünnung |
1:250 - 1:1000 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Native type I collagen from mouse skin |
Collagen I
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
603-1958 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
F, EL |
| Verdünnung |
1:10 - 1:50 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Human Collagen type II from cartilage |
Collagen II
|
Zytomed Systems GmbH |
polyclonal |
500 µl |
Lyophilised |
RUO |
603-1970 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised (for 0.5 ml) |
| Methode |
F, P, EL |
| Verdünnung |
1:10 - 1:40 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Collagen III from human placenta |
Collagen III
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Lyophilised (for 0.5 ml) |
RUO |
603-1974 |
-
|
| Host |
Mouse |
| Klon |
NLI/53 |
| Format |
Lyophilised |
| Methode |
F, P, EL |
| Verdünnung |
1:5 - 1:50 (P) |
| Isotyp |
Mouse IgM |
| Verdünnung |
Native Collagen IV |
Collagen IV
|
Zytomed Systems GmbH |
NLI/53 |
1 ml |
Lyophilised |
RUO |
603-1980 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
F, P, IF, EL, WB |
| Verdünnung |
1:10 - 1:50 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Collagen type IV from human placenta |
Collagen IV
|
Zytomed Systems GmbH |
polyclonal |
500 µl |
Lyophilised |
RUO |
603-1981 |
-
|
| Host |
Mouse |
| Klon |
COL-94 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Basement Membrane |
Collagen IV
|
Diagnostic Biosystems |
COL-94 |
1 ml |
Concentrate |
CE/IVD |
MOB229 |
-
|
| Host |
Mouse |
| Klon |
COL-94 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Basement Membrane |
Collagen IV
|
Diagnostic Biosystems |
COL-94 |
0.1 ml |
Concentrate |
CE/IVD |
MOB229-01 |
-
|
| Host |
Mouse |
| Klon |
COL-94 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Basement Membrane |
Collagen IV
|
Diagnostic Biosystems |
COL-94 |
0.5 ml |
Concentrate |
CE/IVD |
MOB229-05 |
-
|
| Host |
Mouse |
| Klon |
COL-94 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Basement Membrane |
Collagen IV
|
Diagnostic Biosystems |
COL-94 |
6 ml |
Ready-to-use |
CE/IVD |
PDM276 |
-
|
| Host |
Mouse |
| Klon |
COL-94 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Basement Membrane |
Collagen IV
|
Diagnostic Biosystems |
COL-94 |
25 ml |
Ready-to-use |
CE/IVD |
PDM276-25 |
-
|
| Host |
Rabbit |
| Klon |
ZR108 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Purified human placental extract |
| Lokalisation |
Cytoplasm and Cell membrane |
Collagen IV
|
Zeta Corporation |
ZR108 |
1.0 ml |
Concentrate |
CE/IVD |
Z2410RL |
-
|
| Host |
Rabbit |
| Klon |
ZR108 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Purified human placental extract |
| Lokalisation |
Cytoplasm and Cell membrane |
Collagen IV
|
Zeta Corporation |
ZR108 |
7 ml |
Ready-to-use |
CE/IVD |
Z2410RP |
-
|
| Host |
Rabbit |
| Klon |
ZR108 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Purified human placental extract |
| Lokalisation |
Cytoplasm and Cell membrane |
Collagen IV
|
Zeta Corporation |
ZR108 |
0.5 ml |
Concentrate |
CE/IVD |
Z2410RS |
-
|
| Host |
Rabbit |
| Klon |
ZR108 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Purified human placental extract |
| Lokalisation |
Cytoplasm and Cell membrane |
Collagen IV
|
Zeta Corporation |
ZR108 |
0.1 ml |
Concentrate |
CE/IVD |
Z2410RT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM177 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified human Collagen IV protein |
| Lokalisation |
Cytoplasm and basement membrane |
Collagen IV
|
Zeta Corporation |
ZM177 |
1 ml |
Concentrate |
CE/IVD |
Z2478ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM177 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified human Collagen IV protein |
| Lokalisation |
Cytoplasm and basement membrane |
Collagen IV
|
Zeta Corporation |
ZM177 |
7 ml |
Ready-to-use |
CE/IVD |
Z2478MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM177 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified human Collagen IV protein |
| Lokalisation |
Cytoplasm and basement membrane |
Collagen IV
|
Zeta Corporation |
ZM177 |
0.5 ml |
Concentrate |
CE/IVD |
Z2478MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM177 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified human Collagen IV protein |
| Lokalisation |
Cytoplasm and basement membrane |
Collagen IV
|
Zeta Corporation |
ZM177 |
0.1 ml |
Concentrate |
CE/IVD |
Z2478MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IHC(P) |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human breast or lung |
| Verdünnung |
1 - 5 µg/ml |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Collagen Type VI from Human and Bovine Placenta |
Collagen VI
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
603-2392 |
-
|
| Host |
Mouse |
| Klon |
3R9/2 |
| Format |
Purified |
| Methode |
FL, F, EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Binds globular head domain of C1q, purified from human plasma |
Complement C1q
|
Zytomed Systems GmbH |
3R9/2 |
100 µl |
Purified |
RUO |
603-2239 |
-
|
| Host |
Mouse |
| Klon |
H13 |
| Format |
Lyophilised |
| Methode |
F, WB |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
Native human C3a |
Complement C3a
|
Zytomed Systems GmbH |
H13 |
50 µg |
Lyophilised |
RUO |
603-1998 |
-
|
| Host |
Sheep |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Sheep IgG |
| Verdünnung |
Purified C3d from pooled activated serum |
Complement C3d
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-2009 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
F, P, IF |
| Verdünnung |
1:20 - 1:80 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to amino acids 1241-1256 of C4 conjugated to KLH |
Complement C4d
|
Zytomed Systems GmbH |
polyclonal |
250 µl |
Purified |
RUO |
603-2016 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
EL |
| Verdünnung |
1:5000 - 1:20.000 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
C.BSA conjugate |
Corticosterone
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-2035 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
COX-2
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP111 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
COX-2
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP111-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
COX-2
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP111-05 |
-
|
| Host |
Rabbit |
| Klon |
SP83 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liver carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to C-terminus of human CTEN protein |
| Lokalisation |
Cytoplasm, Cell Membrane |
cTEN
|
Zytomed Systems GmbH |
SP83 |
1 ml |
Concentrate |
RUO |
520-3834 |
-
|
| Host |
Rabbit |
| Klon |
CAL49 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cell membrane and cytoplasm |
CTLA4
|
Biocare Medical |
CAL49 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3220A |
-
|
| Host |
Rabbit |
| Klon |
CAL49 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cell membrane and cytoplasm |
CTLA4
|
Biocare Medical |
CAL49 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3220B |
-
|
| Host |
Rabbit |
| Klon |
CAL49 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cell membrane and cytoplasm |
CTLA4
|
Biocare Medical |
CAL49 |
6 ml |
Ready-to-use |
CE/IVD |
API3220AA |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
EL, WB |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant mouse IP-10 |
CXCL10 (IP10, Interferon gamma Inducible Protein)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
603-2100 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
EL, WB |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant human IP-10 |
CXCL10 (IP10, Interferon gamma Inducible Protein)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
603-2101 |
-
|
| Host |
Mouse |
| Klon |
4D5 |
| Format |
Purified |
| Methode |
EL, WB |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant human IP-10 |
CXCL10 (IP10, Interferon gamma Inducible Protein)
|
Zytomed Systems GmbH |
4D5 |
500 µg |
Purified |
RUO |
603-2102 |
-
|
| Host |
Mouse |
| Klon |
CD1.1 |
| Format |
Purified |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Small Intestine, Colon |
| Verdünnung |
1:10 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human Cyclin D1 |
Cyclin D1
|
Zytomed Systems GmbH |
CD1.1 |
10 µg |
Purified |
RUO |
603-2112 |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mantle cell lymphoma, breast cancer |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
Cyclin D1
|
Biocare Medical |
SP4 |
7 ml |
Ready-to-use |
CE/IVD |
ALI307G7 |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mantle cell lymphoma, breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
Cyclin D1
|
Biocare Medical |
SP4 |
0.1 ml |
Concentrate |
CE/IVD |
CRM307AK |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mantle cell lymphoma, breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
Cyclin D1
|
Biocare Medical |
SP4 |
0.5 ml |
Concentrate |
CE/IVD |
CRM307BK |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mantle cell lymphoma, breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
Cyclin D1
|
Biocare Medical |
SP4 |
1 ml |
Concentrate |
CE/IVD |
CRM307CK |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mantle cell lymphoma, breast cancer |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
Cyclin D1
|
Biocare Medical |
SP4 |
6 ml |
Ready-to-use |
CE/IVD |
PRM307AA |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Breast Carcinoma, Mantle Cell Lymphoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zytomed Systems GmbH |
SP4 |
0.5 ml |
Concentrate |
RUO |
RBK025-05 |
-
|
| Host |
Rabbit |
| Klon |
EP12 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near C-terminus of human Cyclin D1 protein |
| Lokalisation |
Nucleus |
Cyclin D1
|
Diagnostic Biosystems |
EP12 |
1 ml |
Concentrate |
CE/IVD |
RMAB106 |
-
|
| Host |
Rabbit |
| Klon |
EP12 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near C-terminus of human Cyclin D1 protein |
| Lokalisation |
Nucleus |
Cyclin D1
|
Diagnostic Biosystems |
EP12 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB106-01 |
-
|
| Host |
Rabbit |
| Klon |
EP12 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near C-terminus of human Cyclin D1 protein |
| Lokalisation |
Nucleus |
Cyclin D1
|
Diagnostic Biosystems |
EP12 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB106-05 |
-
|
| Host |
Rabbit |
| Klon |
EP12 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near C-terminus of human Cyclin D1 protein |
| Lokalisation |
Nucleus |
Cyclin D1
|
Diagnostic Biosystems |
EP12 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD106 |
-
|
| Host |
Rabbit |
| Klon |
EP12 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near C-terminus of human Cyclin D1 protein |
| Lokalisation |
Nucleus |
Cyclin D1
|
Diagnostic Biosystems |
EP12 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD106-25 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM178 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mantle cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Synthetic peptide corresponding to residues within aa 200-295 of Cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZM178 |
1 ml |
Concentrate |
CE/IVD |
Z2480ML |
-
|